Get the Stockscreener App
8.91
2.94%
-0.27
Pre-market:
9.32
0.41
+4.60%
Artiva Biotherapeutics Inc stock is traded at $8.91, with a volume of 780.95K.
It is down -2.94% in the last 24 hours and down -8.90% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$9.18
Open:
$9.14
24h Volume:
780.95K
Relative Volume:
1.69
Market Cap:
$432.92M
Revenue:
$251.00K
Net Income/Loss:
$-87.07M
P/E Ratio:
-2.5103
EPS:
-3.5494
Net Cash Flow:
$-80.18M
1W Performance:
+22.56%
1M Performance:
-8.90%
6M Performance:
+95.82%
1Y Performance:
+341.09%
1-Day Range:
$8.5416
$9.23
1-Week Range:
$6.96
$9.77
52-Week Range:
$1.47
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
8.91 | 446.04M | 251.00K | -87.07M | -80.18M | -3.5494 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Artiva: Targeting A New Benchmark In Refractory Rheumatoid Arthritis With AlloNK - RTTNews
Thursday’s insider buys and sells: Healthcare and tech in focus - Investing.com UK
Thursday’s insider buys and sells: Healthcare and tech in focus By Investing.com - Investing.com UK
Major Insider Move Signals Growing Confidence in Artiva Biotherapeutics - TipRanks
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock By Investing.com - Investing.com Nigeria
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock - Investing.com UK
ARTV Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Weakness Phase - newsline.com
ARTV Q1 2026 Earnings: Surprise EPS Miss Amid Pre-Revenue Stage, Stock Gains 6.91%Net Income Trends - The League of Women Voters of Texas
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $41 - Moomoo
ARTV: AlloNK demonstrates strong efficacy and safety in refractory RA, advancing to pivotal phase III - TradingView
ARTV: AlloNK plus rituximab achieves 71% ACR50 at 6 months in refractory RA with strong safety - TradingView
FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis - Traders Union
Artiva Biotherapeutics stock surges on FDA RMAT designation By Investing.com - Investing.com Canada
Artiva Biotherapeutics stock surges on FDA RMAT designation - Investing.com
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today - The Manila Times
AlloNK shows strong clinical results in refractory rheumatoid arthritis; FDA grants RMAT designation - Pluang
Artiva Biotherapeutics Highlights Promising AlloNK Data for B-cell Depletion in Autoimmune Diseases at EULAR 2026 - Quiver Quantitative
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in ... - Caledonian Record
Artiva Biotherapeutics Highlights AlloNK Data Presented At EULAR 2026 And Receives FDA RMAT Designation In Refractory Rheumatoid Arthritis - marketscreener.com
Artiva Biotherapeutics announces positive AlloNK data - grafa.com
ARTV: Pivotal trial in refractory RA to start in late 2024, with durable efficacy and strong financial runway - TradingView
Artiva Stock on Watch with EULAR Data and Jefferies in Play - Bez Kabli
Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis - Traders Union
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Artiva rises after mid-stage trial data for lead asset in rheumatoid arthritis - MSN
Artiva Biotherapeutics (ARTV) Rises 1.84% as Shares Approach ResistanceEnding Diagonal - newsline.com
Major Investor Makes Bold Move Into Artiva Biotherapeutics Stock - TipRanks
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event - Traders Union
Cantor Fitzgerald Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating - Investing.com UK
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating By Investing.com - Investing.com Nigeria
The Bear Cave #327by Edwin Dorsey - The Bear Cave | Edwin Dorsey
ARTV Stock Price, Quote & Chart | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock By Investing.com - Investing.com Nigeria
As Griffith retires, Dittrich returns to Amgen, takes CFO role - BioCentury
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock By Investing.com - Investing.com Nigeria
Artiva names Diego Miralles as president and head of R&D - The Pharma Letter
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock - Investing.com India
Artiva Biotherapeutics, Inc. Appoints New Principal Financial Officer and President in May 2026 - Minichart
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock - Investing.com India
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock By Investing.com - Investing.com India
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock By Investing.com - Investing.com Canada
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock - Investing.com India
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Artiva Biotherapeutics Inc Stock (ARTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 09 '26 |
Buy |
6.91 |
479,039 |
3,310,159 |
15,683,034 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 10 '26 |
Buy |
7.00 |
103 |
721 |
15,683,137 |
| GC Corp. | 10% Owner |
May 11 '26 |
Buy |
11.52 |
1,085,069 |
12,499,995 |
4,391,969 |
| GC Corp. | 10% Owner |
May 11 '26 |
Buy |
11.52 |
347,222 |
3,999,997 |
1,607,734 |
| Raymon Heather | SVP, Research and Development |
May 19 '26 |
Sale |
9.01 |
3,095 |
27,879 |
148,228 |
| Horan Christopher | Chief Tech Operations Officer |
May 19 '26 |
Sale |
9.01 |
7,002 |
63,073 |
293,450 |
| Bush Jennifer | COO, CLO, Compliance Officer |
May 19 '26 |
Sale |
9.01 |
8,790 |
79,179 |
337,920 |
| Banerjee Subhashis | Chief Medical Officer |
May 19 '26 |
Sale |
9.01 |
7,037 |
63,386 |
144,963 |
| Aslan Fred | Chief Executive Officer |
May 19 '26 |
Sale |
9.01 |
27,116 |
244,253 |
1,535,082 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):